一线和二线线性探针法诊断耐药结核病的不可操作结果、准确性及影响,包括涂片阴性标本,在高通量实验室中的表现
在高通量实验室中,对951例Xpert MTB/RIF检测个体的痰标本常规进行Genotype MTBDRplus和MTBDRsl(均为第2版)检测,以表型药敏试验为二线药物参考标准。涂片阴性标本中MTBDRsl有40%结果不可操作,导致漏检耐药,但可操作结果在判定耐药方面准确。异烟肼药敏试验仍至关重要。
要点
- 涂片阴性标本中MTBDRplus有19%(92/476)结果不可操作,MTBDRsl有40%(171/427)结果不可操作。
- 涂片阴性标本中MTBDRsl对氟喹诺酮类的敏感性为84%(95%CI 67%-93),对二线注射药的敏感性为81%(95%CI 54%-95%)。
- MTBDRsl应用后二线药敏报告时间从37天缩短至6天(P < .001)。
核心结论
- 涂片阴性标本中MTBDRsl有4/10未产生结果,导致大量耐药漏检;但若产生可操作结果,则在判定耐药方面准确。
- 异烟肼药敏试验仍至关重要。
研究设计与样本
- 对951例Xpert MTB/RIF检测个体的痰标本常规进行Genotype MTBDRplus和MTBDRsl(均为第2版)检测,以表型药敏试验为二线药物参考标准.
- 结果不一致的标本进行Sanger测序。
主要发现
- 951例中89%(849/951)培养阳性,其中56%(476/849)涂片阴性。
- 涂片阴性标本中MTBDRplus有19%(92/476)至少1个不可操作结果;MTBDRsl有40%(171/427)不可操作(28%(120/427)假阴性TB,17%(51/427)不确定)。
- 涂片阴性标本中MTBDRsl对氟喹诺酮类的敏感性为84%(95%CI 67%-93),对二线注射药为81%(95%CI 54%-95),对两者为57%(95%CI 28%-82%)。
- 涂片阴性标本中MTBDRsl对氟喹诺酮类的特异性为93%(95%CI 89%-98%),对二线注射药为88%(95%CI 81%-93%),对两者为97%(95%CI 91%-99%)。
- Xpert利福平耐药标本中23%(172/746)为MTBDRplus异烟肼敏感。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rapid tuberculosis (TB) drug susceptibility testing (DST) is crucial. Genotype MTBDRsl is a widely deployed World Health Organization (WHO)-endorsed assay. Programmatic performance data, including non-actionable results from smear-negative sputum, are scarce. METHODS: Sputa from Xpert MTB/RIF individuals (n = 951) were routinely-tested using Genotype MTBDRplus and MTBDRsl (both version 2). Phenotypic DST was the second-line drug reference standard. Discrepant results underwent Sanger sequencing. FINDINGS: 89% (849 of 951) of individuals were culture-positive (56%, 476 of 849 smear-negative). MTBDRplus had at least 1 nonactionable result (control and/or TB-detection bands absent or invalid, precluding resistance reporting) in 19% (92 of 476) of smear-negatives; for MTBDRsl, 40% (171 of 427) were nonactionable (28%, 120 of 427 false-negative TB; 17%, 51 of 427 indeterminate). In smear-negatives, MTBDRsl sensitivity for fluoroquinolones was 84% (95% confidence interval, 67%-93), 81% (54%-95%) for second-line injectable drugs, and 57% (28%-82%) for both. Specificities were 93% (89%-98%), 88% (81%-93%), and 97% (91%-99%), respectively. Twenty-three percent (172 of 746) of Xpert rifampicin-resistant specimens were MTBDRplus isoniazid-susceptible. Days-to-second-line-susceptibility reporting with the programmatic advent of MTBDRsl improved (6 [5-7] vs 37 [35-46]; P < .001). CONCLUSIONS: MTBDRsl did not generate a result in 4 of 10 smear-negatives, resulting in substantial missed resistance. However, if MTBDRsl generates an actionable result, that is accurate in ruling-in resistance. Isoniazid DST remains crucial. This study provides real-world, direct, second-line susceptibility testing performance data on non-actionable results (that, if unaccounted for, cause an overestimation of test utility), accuracy, and care cascade impact.
引用
- Pillay S, de Vos M, Derendinger B, et al. Non-actionable Results, Accuracy, and Effect of First- and Second-line Line Probe Assays for Diagnosing Drug-Resistant Tuberculosis, Including on Smear-Negative Specimens, in a High-Volume Laboratory. Clin Infect Dis. 2023. PMID: 35788278. doi:10.1093/cid/ciac556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。